Compare SLDB & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SLDB | MYGN |
|---|---|---|
| Founded | 2013 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 498.6M | 429.7M |
| IPO Year | 2017 | 1996 |
| Metric | SLDB | MYGN |
|---|---|---|
| Price | $6.15 | $5.35 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 10 | 9 |
| Target Price | ★ $14.70 | $8.06 |
| AVG Volume (30 Days) | 1.1M | ★ 1.2M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 36.65 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $8,094,000.00 | ★ $771,400,000.00 |
| Revenue This Year | N/A | $7.19 |
| Revenue Next Year | N/A | $5.64 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 2.33 |
| 52 Week Low | $2.45 | $3.76 |
| 52 Week High | $7.37 | $11.44 |
| Indicator | SLDB | MYGN |
|---|---|---|
| Relative Strength Index (RSI) | 50.64 | 55.17 |
| Support Level | $5.08 | $4.82 |
| Resistance Level | $6.25 | $5.67 |
| Average True Range (ATR) | 0.42 | 0.40 |
| MACD | -0.02 | 0.14 |
| Stochastic Oscillator | 70.08 | 72.98 |
Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.